Denali Therapeutics Inc. 8-K Summary
Business Context and Reporting Period
Denali Therapeutics Inc. (DNLI), an emerging growth company, filed this Form 8-K on May 8, 2019. The filing serves to announce the financial results for the first quarter ended March 31, 2019. The full details are contained in a press release attached as Exhibit 99.1.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being included in the attached press release (Exhibit 99.1) but are not present in the 8-K body text itself.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. Investors must refer to the attached press release for comparative analysis.
Guidance, Outlook, and Risks
The filing text does not include specific guidance, outlook, management commentary, or risk factors. It explicitly states that the information furnished in Item 2.02 and Item 9.01, including the press release, is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference in other filings unless expressly stated.
Key Facts for Investor Verification
- Verify the specific Q1 2019 financial results (revenue, net loss, cash position) in the attached Exhibit 99.1 press release.
- Confirm the company's status as an emerging growth company that has elected not to use the extended transition period for new accounting standards.
- Note that the financial data in this 8-K is not considered "filed" under Section 18 of the Exchange Act.
- Review the press release for any updates on clinical trials or pipeline progress not detailed in this summary.